Immediate protection of swine from foot-and-mouth disease: A combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine

Vaccine

Volumn 22, Issue 2, 2003, Pages 268-279

  Moraes, Mauro P ^a,b   Chinsangaram, Jarasvech ^a,c   Brum, Mario C S ^a   Grubman, Marvin J ^a  

^a PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^b FEDERAL UNIVERSITY OF VIÇOSA   (Brazil)

^c Therion Biologics Corporation   (United States)

Author keywords

Adenovirus; Foot and mouth disease; Interferon

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CAPSID PROTEIN; FOOT AND MOUTH DISEASE VACCINE; NEUTRALIZING ANTIBODY; PROTEINASE; SUBUNIT VACCINE; VIRUS VACCINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEVER; FOOT AND MOUTH DISEASE; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INOCULATION; LETHARGY; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROPHYLAXIS; PROTEIN EXPRESSION; SEROTYPE; STATISTICAL SIGNIFICANCE; SWINE; VIRUS CAPSID; VIRUS RECOMBINANT; VIRUS VIRULENCE;

EID: 0038409716     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00560-7     Document Type: Article

References (45)

1. Bachrach HL. Foot-and-mouth disease: world-wide impact and control measures. In: Kurstak E, Maramorosch K, editors. Viruses and environment. New York: Academic Press; 1978. p. 299-310.
2. Rueckert RR. Picornaviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PH, editors. Virology. Philadelphia, PA: Lippincott-Raven; 1996. p. 609-54.
3. Gibbens J.C., Sharp C.E., Wilesmith J.W., Mansley L.M., Michalopoulou E., Ryan J.B.M.et al. Descriptive epidemiology of the 2001 foot-and-mouth disease epidemic in Great Britain: the first five months. Vet. Rec. 149:2001;729-743.
4. Knowles N.J., Samuel A.R., Davies P.R., Kitching R.P., Donaldson A.I. Outbreak of foot-and-mouth disease virus serotype O in the UK caused by a pandemic strain. Vet. Rec. 148:2001;258-259.
5. Yang P.C., Chu R.M., Chung W.B., Sung H.T. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet. Rec. 145:1999;731-734.
6. Lubroth J., Lopez A., Ramalho A.K., Meyer R.F., Brown F., Darsie G.C. Cattle response to foot-and-mouth disease virus nonstructural proteins as antigens within vaccines produced using different concentrations. Vet. Q. 20:1998;S13-S17.
7. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine. 20:2002;1631-1639.
8. O'Donnell V.K., Smitsaart E., Cetra B.et al. Detection of virus infection associated antigen and 3D antibodies in cattle vaccinated against foot and mouth disease. Rev. Sci. Tech. 16:1997;833-840.
9. Barteling S.J., Vreeswijk J. Developments in foot-and-mouth disease vaccines. Vaccine. 9:1991;75-88.
10. Salt J.S. The carrier state in foot and mouth disease - an immunological review. Br. Vet. J. 149:1993;207-223.
11. Office International des Epizooties (OIE). Foot and mouth disease. In: International animal health code: mammals, birds, and bees. 10th ed. Paris: OIE; 2001. p. 63-74.
12. Mayr G.A., O'Donnell V., Chinsangaram J., Mason P.W., Grubman M.J. Immune responses and protection against foot-and-mouth disease virus (FMDV) challenge in swine vaccinated with adenovirus-FMDV constructs. Vaccine. 19:2001;2152-2162.
13. Chinsangaram J., Moraes M.P., Koster M., Grubman M.J. A novel viral disease control strategy: adenovirus expressing interferon alpha rapidly protects swine from foot-and-mouth disease. J. Virol. 77:2003;1621-1625.
14. Mayr G.A., Chinsangaram J., Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology. 263:1999;496-506.
15. Goodbourn S., Didcock L., Randall R.E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81:2000;2341-2364.
16. Vilcek J, Sen GC. Interferons and other cytokines. In: Fields BN, Knipe DM, Howley PH, editors. Virology. Philadelphia, PA: Lippincott-Raven; 1996. p. 375-99.
17. Ahl R., Rump A. Assay of bovine interferons in cultures of the porcine cell line IB-RS-2. Infect. Immun. 14:1976;603-6066.
18. Chinsangaram J., Koster M., Grubman M.J. Inhibition of L-deleted foot-and-mouth disease virus replication by alpha/beta interferon involves double-stranded RNA-dependent protein kinase. J. Virol. 12:2001;5498-5503.
19. Chinsangaram J., Piccone M.E., Grubman M.J. Ability of foot-and mouth disease virus to form plaques in cell culture is associated with suppression of alpha/beta interferon. J. Virol. 73:1999;9891-9898.
20. Sellers R.F. Multiplication, interferon production and sensitivity of virulent and attenuated strains of the virus of foot-and-mouth disease. Nature. 198:1963;1228-1229.
21. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus 5. J. Gen. Virol. 36:1977;59-72.
22. Moraes M.P., Mayr G.A., Grubman M.J. pAd5-Blue: an easy to use, efficient, direct ligation system for engineering recombinant adenovirus constructs. BioTechniques. 31:2001;1050-1056.
23. Sa-Carvalho D., Rieder E., Baxt B., Rodarte R., Tanuri A., Mason P.W. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:1997;5115-5123.
24. Doel T, Lombard M, Fawthrop D, Schermbrucker C, Dubourget P. Testing of FMD vaccines. European Commission for the control of foot-and-mouth disease. Session of the Research Group of the Standing Technical Committee, Appendix 32. Aldershot, UK; 1998. p. 227-37.
25. Cedillo-Barron L., Foster-Cuevas M., Belsham G.J., Lefevre F., Parkhouse R.M. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J. Gen. Virol. 82:2001;1713-1724.
26. Sanz-Parra A., Jimenez-Clavero M.A., Garcia-Briones M.M., Blanco E., Sobrino F., Ley V. Recombinant viruses expressing the foot-and-mouth disease virus capsid precursor polypeptide (P1) induce cellular but not humoral antiviral immunity and partial protection in pigs. Virology. 259:1999;129-134.
27. Wang C.Y., Chang T.Y., Walfield A.M., Ye J., Shen M., Chen S.P.et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine. 20:2002;2603-2610.
28. Mason P.W., Piccone M.E., McKenna T.St.-C., Chinsangaram J., Grubman M.J. Evaluation of a live-attenuated foot-and-mouth disease virus as a vaccine candidate. Virology. 227:1997;96-102.
29. Haugland RP, You WW. Coupling of monoclonal antibodies with biotin. In: Davis WC, editor. Methods in molecular biology. Monoclonal antibody protocols, vol. 45. Totowa, NJ: Humana Press; 1995. p. 223-33.
30. Grubman M.J., Robertson B.H., Morgan D.O., Moore D.M., Dowbenko D. Biochemical map of polypeptides specified by foot-and-mouth disease virus. J. Virol. 50:1984;579-586.
31. Anon. Key recommendations on FMD and other infectious diseases. News and reports. Vet Rec 2002;151:98-9.
32. Anon. Infectious disease in livestock. London: The Royal Society; 2002.
33. Brassard D.L., Grace M.J., Bordens R.W. Interferon-α as an immunotherapeutic protein. J. Leuk. Biol. 71:2002;565-581.
34. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 14:2001;461-470.
35. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E.et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immun. 169:2002;375-383.
36. 1 interferon on bovine herpesvirus type 1-induced respiratory disease. J. Gen. Virol. 66:1985;2383-2394.
37. Brooks T.J.G., Phillpotts R.J. Interferon-alpha protects mice against lethal infection with St. Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antiviral Res. 41:1999;57-64.
38. Lukaszewski R.A., Brooks T.J.G. Pegylated alpha interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J. Virol. 74:2000;5006-5015.
39. Noisakran S., Campbell I.L., Carr D.J.J. Ectopic expression of DNA encoding IFN-α1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J. Immunol. 162:1999;4184-4190.
40. Rosenquist B.D., Allen G.K. Effect of bovine fibroblast interferon on rhinovirus infection in calves. Am. J. Vet. Res. 51:1990;870-873.
41. Schwers A., Severin J.E., Bublot M., Maenhoudt M., Pastoret P.P., Vanden Broecke C.et al. Protection of cattle from infection with vaccinia virus by bovine interferon αC. Vet. Rec. 125:1989;15-16.
42. Bisceglie A.M.Di., McHutchison J., Rice C.M. New therapeutic strategies for hepatitis C. Hepatology. 35:2002;224-231.
43. Davis G.L. Treatment of chronic hepatitis C. Br. Med. J. 323:2001;1141-1142.
44. Heintges T., Petry W., Kaldewey M., Erhardt A., Wend U.C., Gerlich W.H. et al. Combination therapy of active HbsAg vaccination and interferon-α in interferon-α nonresponders with chronic hepatitis B. Dig. Dis. Sci. 46:2001;901-906.
45. Protzer U., Nassal M., Chiang P.W., Kirschfink M., Schaller H. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10818-10823.